ArticleMolecular pharmaceutics2017
Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe.
Article in Molecular pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Dual-modality theranostics probes: sintegrative strategies for precision management of oncologic malignancies.Life medicine · 2026Review
- Asymmetric rotaxanes as dual-modality supramolecular imaging agents for targeting cancer biomarkers.Communications chemistry · 2023Article
- Targeted Dual-Modal PET/SPECT-NIR Imaging: From Building Blocks and Construction Strategies to Applications.Cancers · 2022Review
- Dual Probes for Positron Emission Tomography (PET) and Fluorescence Imaging (FI) of Cancer.Pharmaceutics · 2022Review
- HydrophilicChemical communications (Cambridge, England) · 2019Article
- The Concept of Drug-Resistant Epileptogenic Zone.Frontiers in neurology · 2019Article
- P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates.Biomaterials science · 2018Article
- P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes.ACS applied materials & interfaces · 2018Article
- P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.Theranostics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Overexpression of P-glycoprotein (Pgp) has been considered a primary cause for multidrug resistance in a variety of cancers for three decades. However, clinical translation of Pgp targeted therapeutics has been hindered by lack of patient preselection based on the Pgp presence in tumors. We aim to develop a molecularly targeted probe for imaging tumoral Pgp in vivo with positron emission tomography (PET) and fluorescence, and to provide a tool for preselecting the patients with tumoral Pgp expression. Thus, a Pgp monoclonal antibody 15D3 was chemically modified with IRDye800 (IR800) and DOTA chelator. The specificity of the antibody conjugates DOTA-Pab-IR800 was verified in Pgp-expressing 3T3-MDR1 and control 3T3 cells. After radiolabeling with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.